Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

ZymoGenetics initiates rFXIII phase I trials, signs exclusive licensing agreement

Feb. 7, 2003

MIT details the rational design of LMWHs with improved properties

Feb. 6, 2003

Baxter proposes Advate as brand name for rAHF-PFM

Feb. 6, 2003

Research term extended in 3DP thrombin collaboration

Feb. 6, 2003

Boehringer Ingelheim presents novel thrombin inhibitors

Feb. 6, 2003

Novel factor Xa inhibitors developed at BMS

Feb. 5, 2003

First treatment for acute ischemic stroke cleared for use in Europe

Jan. 29, 2003

Novel antagonists of platelet ADP (P2YAC) receptors discovered at Schering AG

Jan. 23, 2003

Novel factor Xa inhibitors and their use covered by Millennium patent

Jan. 16, 2003

Bicyclic factor Xa inhibitors designed by BMS scientists

Jan. 14, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...